peristalsis 3:3, 4, 9, 45, 52, 82,83,
221
peritoneal cavity 3:16, 82
peritonitis 3: 15 , 82–83,86, 93;
4: 287
peritonsillar abscess 1:44
permanent teeth 1:294, 358
persistent vegetative state 1: 244 ,
277
personal health history 4: 28 ,
40–41, 44
personal hygiene 4:41
acne 1:132–133
addiction 4: 314
community sanitation 4: 18
enteral nutrition 4: 183
hand washing 4:26
preventive medicine 4: 3
sneeze/cough etiquette 2:354
wound care 4: 281
pertussis 1:6; 2:348–349; 4: 17
pessary 3:185, 350
petechiae 1:183; 2:137, 142
Peyer’s patches 2: 265 , 289
Peyronie’s disease 3:318–319, 338
phagocyte 2:162, 255 ,283–284;
4: 114
phagocytosis 2:162
cancer treatment options and
decisions 2: 370
complement cascade 2: 255
hemolysis 2: 143
immune system 2: 235
immunoglobulin 2: 275
leukocyte 2: 148
lymph node 2: 151
spleen 2: 167
phantom pain 1:382–383
pharmacodynamics 4:168
pharmacogenomics 4:112, 147
pharmacokinetics 4:168–169
pharmacopeia 4:169
pharyngitis 1:5, 22, 45, 45
pharynx 1:45, 57
phenazopyridine (Pyridium) 3:184,
226
phencyclidine (PCP) 4: 338 , 348,
348, 348t
phenotype 4:136
phenylketonuria (PKU) 4: 130 ,
136–138, 137 t, 226, 227t
pheochromocytoma 3:109, 151,
152 , 154
phimosis 3:248, 262, 319, 319
phlebotomy 2:122, 128, 162, 164
phobia 3:376, 379, 379–380, 380 t
phosphate 4:186, 187
phosphodiesterase (PDE) inhibitors
3:238, 279
photophobia 1:95, 100, 107–108,
136; 4: 338
photosensitivity 1:183–184, 193
phototherapeutic keratectomy
(PTK) 1:108, 108 t
phototherapy 1:184
physical abuse 4:242, 245
physical activity recommendations
4:38, 215, 222, 228–229
physical exercise and cardiovascular
health 2: 73 , 97, 106
physical fitness. Seefitness
physical inactivity 4:15, 28, 210,
211, 291, 301
physical therapy 1:349
phytochemicals 4:177, 193
phytoestrogens 4: 83 , 94–95, 94 t,
95 t, 99
PID. Seepelvic inflammatory disease
piercings 1:14, 39, 184–185
pilonidal disease 1:185–186
pineal gland 1:65, 229; 3:100, 151,
154–155; 4: 88
pinguecula 1:108
pituitary gland 1:175, 229;
3:155–156
acromegaly 3: 104
ACTH 3: 110
ADH 3: 113
adrenal insufficiency 3: 109
aging and endocrine changes
3: 111
anabolic steroids and steroid
precursors 4: 322
breast 3: 250
CRH 3: 116
Cushing’s syndrome 3: 117
diabetes insipidus 3: 122
endocrine system 3:98–99
FSH 3: 127
GH 3: 131
GHRH 3: 131
GnRH 3: 129
hGH supplement 4: 76
hyperprolactinemia 3: 139
hyperthyroidism 3: 139
hypopituitarism 3: 143
hypothalamus 3: 144
hypothyroidism 3: 146
inhibin 3: 148
LH 3: 151
MEN 3: 151
menstrual cycle 3: 303oxytocin 3: 152
prolactin 3: 157
SAD 3: 382
sleep disorders 3: 384
TSH 3: 164
pityriasis rosea 1:186
placebo 4: 68 , 169
placenta 2:9–10, 131; 3:319–320,
319 t
childbirth 3: 262
CVS 3: 262
estrogens 3: 126
gestational diabetes 3: 289
LH 3: 151
umbilical cord 3: 349
plantar fasciitis 1:349–350
plantar warts 2:336, 337
plaque, skin 1:173–174, 186, 189
plasma 2:162–163
albumin 2: 124
blood 2: 118
bone marrow 2: 132
gammaglobulin 2:262, 263
immune response 2: 273
immune system 2: 236
inflammation 2: 277
leukocyte 2: 148
plasma cells 2:236, 239, 245, 246,- See alsoB-cell lymphocyte
plasmapheresis 1:205; 2:129, 142
plasmid transfer 4:150–151
Plasmodiumsp. 2:342, 343
plastic surgery 1:41, 47, 75; 3:256,
299; 4: 274 , 274–275, 275 t, 287
platelet 2:119, 132, 137, 141, 148,
163,170, 171
platelet aggregation 2:163; 4: 69
anticoagulation therapy 2: 14
aspirin therapy 2: 20
coagulation 2: 136
hemophilia 2: 143
medications to treat
cardiovascular disease
2:78–79
NSAIDs 2: 287
platelet 2: 119
prostaglandins 2:289–290
von Willebrand’s disease 2: 174
platinum compounds (for
chemotherapy) 2:376, 376t
pleura 2:218
pleural cavity 2:218, 219, 232
pleural effusion 2: 190 , 218, 218 ,
218,218, 219
pleural rub 2:195, 219
pleural space 2:218, 223
Index 497